Lucid Diagnostics Inc
NASDAQ:LUCD
Gross Margin
Lucid Diagnostics Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
116.2m USD |
-63%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
224.3B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.1B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.7B USD |
69%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.8B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.8B USD |
66%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.8B EUR |
38%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.3B USD |
45%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.5B USD |
79%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
35.4B USD |
61%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.7B CNY |
64%
|
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Lucid Diagnostics Inc's most recent financial statements, the company has Gross Margin of -63.4%.
You don't have any saved screeners yet